Table 3.

Combination antibody therapies under investigation

Start year for vaccine trials including mAB combinations
	Start year	1997	1998	1999	2000	2001	2002	2004	2005	2006	2008	2009	2010	2011	2012	2013	2014	2015	Total
Anti-idiotypic antibody	3H1					1													1
	Lung					1													1
	BEC2 mab		1	1															2
	Lung		1	1															2
	Racotumomab												1						1
	NSCLC												1						1
Targeted	Bevacizumab											1	2		1	1			5
	Brain															1			1
	Colorectal Cancer												1						1
	Lung												1						1
	Ovarian Cancer														1				1
	Renal Cell Cancer (RCC)											1							1
	Cetuximab								1					1					2
	Colorectal Cancer													1					1
	Pancreatic Cancer								1										1
	Erlotinib													1					1
	NSCLC													1					1
	Trastuzumab (Herceptin)							1	1	1	1	1			1	1			7
	Breast Cancer							1	1	1	1	1			1	1			7
	Rituximab				1			2		1		2							6
	Leukemia									1									1
	Lymphoma				1			2				2							5
Immune-suppressive	Daclizumab													1					1
	Melanoma													1					1
	muromonab-CD3	2						1											3
	Brain	1																	1
	Melanoma	1						1											2
Checkpoint inhibitor	Ipilimumab						1	3		1						1	1		7
	Melanoma						1	3		1							1		6
	Pancreatic Cancer															1			1
	nivolumab																	1	1
	Pancreatic Cancer																	1	1
	Pidilizumab (CT-011)												2	1	1				4
	Leukemia												1						1
	Myeloma												1						1
	Neoplasm														1				1
	Renal Cell Cancer (RCC)													1					1
	Total	2	1	1	1	1	1	7	2	3	1	4	5	4	3	3	1	1	41